

34. Laco J, Podhola M, Kamarádová K, et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. *Virchows Archiv*. 2013;463(5):721-730.
35. Hermanová M: Idiopatická retroperitoneální fibróza - editorial. *Vnitřní lékařství*. 2011;57(5):439-440.
36. Michaligová A, Plank L, Ježíková, A, et al. Ormondova choroba (idiopatická retroperitoneální fibróza). *Vnitřní lékařství*. 2011;57(5):511-515.
37. Amis ES. Retroperitoneal fibrosis. *AJR Am J Roengenol*. 1991;157(2):321-329.
38. Sanders RC, Duffy T, Mcloughlin MG, Walsh PC. Sonography in the diagnosis of retroperitoneal fibrosis. *J Urol*. 1977;118(6):944-946.
39. Vivas I, nicolas AI, Velazquez P, Elduayen B, fernandez-Villa T, Martinez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestation. *Br j Radiol* 2000;73(866):214-222.
40. Van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prostective evaluation of incidence and clinicoradiologic presentation. *Medicine (Baltimore)* 2009;88(4):193-201.
41. Caiafa RO, Vinuesa AS, Izquierdo RS, Brufau BP, Colella JRA, Molina CN. Retroperitoneal fibrosis: role of imaging in Diagnosis and Follow-up. *RadioGraphics*. 2013 33:2,535-552.
42. Miniberger M, Kašpar M, Drechslerová, et al. Ormondův syndrom (Syndrom retroperitoneální fibrózy). Diagnostické obtíže u necharakteristické formy onemocnění při vyšetření výpočetní tomografií. *Česká radiologie*. 1998;52(4):214-220.
43. Řehák Z, Němec P, Fabian, et al. Využití pozitronové emisní tomografie (18F-FDG PET) v diagnostice idiopatické retroperitoneální fibrózy – kazuistika Slovenská rádiológia. 2009;16(1):68-73.
44. Rousset E, Callemeyn J, Van Moerkercke W. Standardized approach to idiopathic retroperitoneal fibrosis: a comprehensive review of the literature. *Acta Clin Belg*. 2020;75(4):239-244.
45. Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. *PLoS One*. 2021;16(2):e0245601. doi: 10.1371/journal.pone.0245601.
46. Novák I, Morávek P, Baše J, et al. Dlouhodobé výsledky léčby nemocných s retroperitoneální fibrózou. *Rozhledy v chirurgii*. 1994;73(6):287-290.
47. Radoňák J, Vajo J, Toncr I, et al. Neobvyklá lokalizovaná forma retroperitoneální fibrózy. *Rozhledy v chirurgii*. 1999;78(8):378-380.
48. van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. *Am J Kidney Dis*. 2007;49:615-625.
49. Mizushima I, Inoue D, Yamamoto M, et al. Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarthritis: a retrospective multicenter study. *Arthritis Res Ther*. 2014;16:R156. doi:10.1186/ar4671
50. Brandt AS, Kamper L, Kukuk S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. *Urol Int*. 2014;93:320-325.
51. van Bommel EF, Pelkmans LG, van Damme H, et al. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. *Eur J Intern Med*. 2013;24:444-450.
52. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomized controlled trial. *Lancet*. 2011;378:338-346.
53. Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. *Clin Rheumatol*. 1995;14(4):481-484.
54. Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. *Ann Rheum Dis*. 2013;72:1584-1586.
55. Scavalli AS, Di Rocco G, Giannotti D, et al. Two-years follow-up of low-dose methotrexate and 6-methylprednisolone therapy in a patient with idiopathic retroperitoneal fibrosis. *Eur Rev Med Pharmacol Sci*. 2012;16(15):2171-4.
56. Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. *Ann Rheum Dis*. 2012;71:311-312.
57. Kohler HP, Laeng RH, Egger C, et al. Systemische Fibrose (generalisierte Form des Morbus Ormond). Bericht über einen Fall, der mit Cyclophosphamid und Kortikosteroiden eine komplette Remission erlangte. *Schweiz Med Wochenschr*. 1995;125(44):2131-6.
58. Colomer Rubio E, Blanes Gallego A, et al. Mesenteric panniculitis with retroperitoneal involvement resolved after treatment with intravenous cyclophosphamide pulses. *An Med Interna*. 2003;20 (1):31-33.
59. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. *Nephrol Dial Transplant*. 2006;21:2485-90.
60. Průcha M, Kolombo I, Štádl P. Combination of steroids and azathioprine in the treatment of Ormond's disease – a single centre retrospective analysis. *Prague Med Rep*. 2016;117:34-41. doi:10.14712/23362936.2016.3
61. Grotz W, von Zedtwitz I, Andre M, et al. Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. *Lancet*. 1998;352(9135):1195.
62. Witschi M, Gugger M, Nicod LP. Treatment of mediastinal fibrosis with mycophenolate mofetil. *Respiration*. 2009;78(3):330-333.
63. Adler S, Lodermeier S, Gaa J, et al. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. *Rheumatology (Oxford)*. 2008;47(10):1535-1538.
64. Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. *Rheumatology (Oxford)*. 2007;46(4):717-718.
65. Khalil F, Mir MA, Venuto RC. Mycophenolate mofetil in the treatment of retroperitoneal fibrosis. *Clin Rheumatol*. 2008;27(5):679-681.
66. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. *Ann Intern Med*. 2011;154:31-36.
67. Scheel PJ Jr, Piccini J, Rahman MH, et al. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. *J Urol*. 2007;178(1):140-143.
68. Swartz RD, Lake AM, Roberts WW, et al. Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. *Clin Nephrol*. 2008;69(4):260-268.
69. Marzano A, Trapani A, Leone N, et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. *Ann Rheum Dis*. 2001;60(4):427-8.
70. Al-Harthy F, Esdaile J, Berean KW, et al. Multifocal idiopathic fibrosclerosis: treatment of 2 cases with cyclosporine. *J Rheumatol*. 2006;33(2):358-61. PMID: 16465670.
71. Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. *Am J Med*. 2004;116:194-197.
72. Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. *Ann Rheum Dis*. 2012;71:1262-1264.
73. Almeqdadhi M, Al-Dulaimi M, Perepletchikov A, et al. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review. *Clin Nephrol Case Stud*. 2018;6:4-10.
74. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. *Ann Rheum Dis*. 2015;74:1171-1177.
75. Dedinská I, Svetlík D, Adamicova K, et al. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab. *Iran J Kidney Dis*. 2016;10(5):332-335.
76. Hamdan A, Moeen Z, Tariq H, et al. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. *Cureus*. 2021;13(9):e17940. doi:10.7759/cureus.17940.
77. Wallwork R, Wallace Z, Perugini C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. *Medicine (Baltimore)*. 2018;97(42):e12631. doi: 10.1097/MD.00000000000012631.
78. Boyeva V, Alabisi H, Seidman MA, et al. Use of rituximab in idiopathic, retroperitoneal fibrosis. *BMC Rheumatol*. 2020;4:40. doi: 10.1186/s41927-020-00140-9.
79. Urban ML, Maritati F, Palmisano A, et al. F. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. *Ann Rheum Dis*. 2020;79(3):433-434.
80. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. *Curr Rheumatol Rep*. 2021;23(3):18. doi: 10.1007/s11926-020-00966-9.
81. Dattani R, Barwick TD, El Wardany G, et al. RaDaR Rare Disease Group (RDG). An international patient-centred study of retroperitoneal fibrosis. *QJM*. 2022;115(3):148-154. doi: 10.1093/qjmed/hcaa327.
82. Hanazono A, Sanpei Y, Shimada H, et al. Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. *eNeurologicalSci*. 2022;29:100428. doi: 10.1016/j.ensci.2022.100428.
83. Benucci M, Damiani A, Li Gobbi F, et al. Jaccoud's arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment. *Reumatismo*. 2017;69(2):88-91.
84. Perrotta FM, Fici M, Guerra G, et al. Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. *Clin Exp Rheumatol*. 2017;35 Suppl 103(1):226-227.
85. Vaglio A, Catanoso MG, Spaggiari L, et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. *Arthritis Rheum*. 2013;65(9):2469-75.
86. Loricera J, Blanco R, Castaeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. *Clin Exp Rheumatol*. 2014;32(3 Suppl 82):S79-89.
87. Catanoso MG, Spaggiari L, Magnani L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. *Clin Exp Rheumatol*. 2012;30(5):776-8.
88. Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. *Ann Rheum Dis*. 2023;ard-2022-223736. doi:10.1136/ard-2022-223736.
89. Hirose M, Ishimaru Y, Sakata S, et al. Rapid Shrinkage of Retroperitoneal Lymphangiomyoma after Sirolimus Initiation. *Intern Med*. 2022;61(13):2081-2082. doi: 10.2169/internalmedicine.8685-21.
90. Yao W, Li K, Wang Z, et al. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus. *Pediatr Dermatol*. 2020;37(4):677-680. doi: 10.1111/pde.14157.
91. Lecuelle D, Basille D, Renard C, et al. Highly effective sirolimus therapy for abdominal lymphangiomyoma. *Respir Med Res*. 2019;75:32-34. doi: 10.1016/j.resmer.2019.02.002.
92. Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. *Eur J Intern Med*. 2020;74:92-98. doi: 10.1016/j.ejim.2019.12.029.